このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Asensus Surgical 将来の成長

Future 基準チェック /26

Asensus Surgicalは、52.8%と49.8%でそれぞれ年率52.8%で利益と収益が成長すると予測される一方、EPSはgrowで55.3%年率。

主要情報

52.8%

収益成長率

55.3%

EPS成長率

Medical Equipment 収益成長	16.7%
収益成長率	49.8%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	16 May 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

NYSEAM:ASXC - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	51	-26	N/A	N/A	1
12/31/2025	22	-61	N/A	N/A	2
12/31/2024	12	-66	N/A	N/A	2
3/31/2024	9	-79	-61	-60	N/A
12/31/2023	9	-78	-64	-64	N/A
9/30/2023	6	-79	-65	-64	N/A
6/30/2023	7	-80	-65	-64	N/A
3/31/2023	7	-79	-61	-60	N/A
12/31/2022	7	-76	-60	-59	N/A
9/30/2022	7	-74	-59	-58	N/A
6/30/2022	7	-71	-54	-52	N/A
3/31/2022	7	-64	-48	-46	N/A
12/31/2021	8	-62	-42	-41	N/A
9/30/2021	7	-60	-41	-40	N/A
6/30/2021	5	-59	-41	-40	N/A
3/31/2021	5	-60	-45	-44	N/A
12/31/2020	3	-60	-47	-47	N/A
9/30/2020	3	-60	-48	-48	N/A
6/30/2020	4	-143	-59	-59	N/A
3/31/2020	7	-149	-62	-62	N/A
12/31/2019	9	-154	-74	-73	N/A
9/30/2019	15	-147	-73	-72	N/A
6/30/2019	19	-69	-69	-69	N/A
3/31/2019	22	-83	-61	-60	N/A
12/31/2018	24	-62	-49	-48	N/A
9/30/2018	20	-131	-46	-45	N/A
6/30/2018	15	-150	-42	-41	N/A
3/31/2018	10	-130	-47	-46	N/A
12/31/2017	7	-145	N/A	-47	N/A
9/30/2017	4	-83	N/A	-53	N/A
6/30/2017	5	-57	N/A	-50	N/A
3/31/2017	3	-122	N/A	-51	N/A
12/31/2016	2	-120	N/A	-52	N/A
9/30/2016	1	-120	N/A	-51	N/A
6/30/2016	N/A	-121	N/A	-50	N/A
3/31/2016	N/A	-50	N/A	-45	N/A
12/31/2015	N/A	-47	N/A	-39	N/A
9/30/2015	0	-41	N/A	-34	N/A
6/30/2015	0	-39	N/A	-36	N/A
3/31/2015	0	-40	N/A	-35	N/A
12/31/2014	0	-38	N/A	-33	N/A
9/30/2014	0	-38	N/A	-31	N/A
6/30/2014	1	-37	N/A	-27	N/A
3/31/2014	1	-31	N/A	-24	N/A
12/31/2013	1	-28	N/A	-21	N/A
9/30/2013	2	-24	N/A	-17	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ASXC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ASXC今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ASXC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ASXCの収益 ( 49.8% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: ASXCの収益 ( 49.8% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ASXCの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Asensus Surgical 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates fall by 20%

Consensus revenue estimates increase by 10%

Asensus Surgical, Inc. Provides Unaudited Earnings Guidance for the Quarter and Full Year Ending on December 31, 2023

Consensus EPS estimates fall by 23%

Consensus revenue estimates fall by 34%

Price target decreased by 21% to US$1.75

Recent updates

New major risk - Share price stability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 20%

Asensus Surgical, Inc. to Report Q1, 2024 Results on May 14, 2024

KARL STORZ SE & Co. KG entered into an agreement to acquire Asensus Surgical, Inc. (NYSEAM:ASXC) for $100 million.

Full year 2023 earnings: EPS exceeds analyst expectations

Asensus Surgical, Inc. to Report Q4, 2023 Results on Mar 21, 2024

President exercised options and sold US$131k worth of stock

Consensus revenue estimates increase by 10%

Asensus Surgical, Inc. Provides Unaudited Earnings Guidance for the Quarter and Full Year Ending on December 31, 2023

Asensus Surgical, Inc. Develops the LUNA Surgical System

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Asensus Surgical, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings: EPS misses analyst expectations

Asensus Surgical, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New minor risk - Share price stability

Consensus EPS estimates fall by 23%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 34%

Price target decreased by 21% to US$1.75

Full year 2022 earnings: EPS exceeds analyst expectations

President exercised options and sold US$406k worth of stock

Asensus Surgical, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022

Insufficient new directors

Consensus revenue estimates fall by 17%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$2.25

Asensus Surgical, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Asensus Surgical, Inc. Announces Impairment Charges for Three Months Ended June 30, 2022

Asensus Surgical, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Asensus Surgical, Inc. to Showcase the Senhance Surgical System and Performance-Guided Surgery in Upcoming Society of Robotic and Digital Surgery Conference

Asensus Surgical, Inc., Annual General Meeting, Jun 14, 2022

Asensus Surgical, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Asensus Surgical, Inc. Announces Purchase of Senhance Robotic System by Loginov Moscow Clinical Scientific Center

Asensus Surgical Receives FDA 510(k) Clearance for Expansion of Machine Vision Capabilities

Asensus Surgical, Inc. to Report Q4, 2020 Results on Mar 11, 2021

Asensus Surgical Announces FDA Clearance in General Surgery

TransEnterix, Inc. has completed a Follow-on Equity Offering in the amount of $69.249999 million.

TransEnterix, Inc. has completed a Follow-on Equity Offering in the amount of $31.25 million.

TransEnterix, Inc. Announces Southern Surgical Hospital to Initiate a Senhance Digital Laparoscopic Program

TransEnterix Announces Approval of Senhance Surgical System in Russian Federation

Transenterix, Inc. Does Not Provide Forward-Looking Guidance

TransEnterix, Inc. to Report Q3, 2020 Results on Nov 05, 2020

TransEnterix, Inc. Announces First Pediatric Surgical Cases with Senhance® Surgical System

TransEnterix Announces Toshima Hospital in Japan to Initiate A Senhance® Digital Laparoscopy Program

Transenterix, Inc. Not Provide Revenue Guidance

TransEnterix, Inc. Contemplates Bankruptcy

TransEnterix, Inc. to Report Q2, 2020 Results on Aug 05, 2020

TransEnterix, Inc.(AMEX:TRXC) dropped from Russell Microcap Growth Index

TransEnterix, Inc.(AMEX:TRXC) dropped from Russell 2000 Dynamic Index

TransEnterix, Inc.(AMEX:TRXC) dropped from Russell Microcap Value Index

TransEnterix, Inc.(AMEX:TRXC) dropped from Russell 2500 Growth Index

TransEnterix, Inc.(AMEX:TRXC) dropped from S&P Global BMI Index

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘